MILAN, Italy, Oct. 17, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX) will host a conference call on Friday, November 9, 2007 at 8:00 AM Eastern Daylight Time, 2:00 PM Central European Time reporting third quarter 2007 financial results. The conference call to review the results will be hosted by Gearoid Faherty, Chief Executive Officer, and Mario Crovetto, Chief Financial Officer. Conference call schedule:
7:30 AM EDT: Third quarter 2007 financial results will be released
7:50 AM EDT: To participate in the conference call:
-- US Participants dial 1.888.935.4575
-- International Participants dial +1.718.354.1385
8:00 AM EDT: Conference call begins promptly
Call Replay: A replay of the call will be available until November
16, 2007. The passcode to access the replay is 4483027.
-- US Participants dial 1.866.883.4489
-- International Participants dial +1.718.354.1112
Live audio of the conference call will be simultaneously broadcast over the Internet. This event can be accessed by visiting Eurand's website at www.eurand.com. Following the live webcast, the archived version of the call will be available at the same URL until November 16, 2007.
About Eurand
Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate, Zentase, for the treatment of Exocrine Pancreatic Insufficiency and filed a rolling NDA for this product which the company anticipates to complete by the end of 2007. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation.
Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at www.eurand.com.
This release includes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward-looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.